Hepatic regeneration in a rat model is impaired by chemotherapy agents used in metastatic colorectal cancer.
(2015) European Journal of Surgical Oncology — Vol. 41, n° 11, p. 1471-1478 (2015)
Files
101HubertEurJSurgicalonclol2015.pdf
Open Access - Adobe PDF
- 1.1 MB
Details
- Authors
- Abstract
- Administering Oxaliplatin prior to resection of colorectal liver metastases often induces a Sinusoidal Obstruction Syndrome (SOS), which can affect postoperative patient outcome. Bevacizumab (Anti-VEGF-A) can decrease the severity of SOS and the associated risk of postoperative liver failure. We investigated the impact of both Oxaliplatin (Oxali) and Bevacizumab on liver regeneration in a rat model. Male Wistar rats underwent a 70% partial hepatectomy (PH) 3 days after a 2 ml intraperitoneal injection of either saline (controls, n = 17), or Oxaliplatin 10, 20 or 50 mg/kg, 5-Fluorouracil 100 mg/kg (5-FU) and Bevacizumab 5 or 10 mg/kg in various combinations (total 98 rats, 11 groups, n = 5-18/group). Liver regeneration was assessed by remnant liver weight recovery and cell proliferation by immunodetection of BrDU incorporation (days 1, 2, 3, 7). Hepatic mRNA expression levels of VEGF-A and of its 2 receptors (Flt-1 and KDR) were quantified by PCR technique. Liver regeneration was impaired for 3 days post PH by Oxali 20 alone and Oxali 10 + 5-FU, without any rescue effect by neither Bevacizumab 5 nor 10 mg/kg. Unlike in humans, there were no sinusoidal changes. VEGF-A mRNA expression and receptor 2 (KDR) expressions decreased 24 h post PH in a similar fashion in controls, Oxali 20 and Oxali 10 + 5-FU groups. All groups had recovered over 60% of their liver weight by day 7. Oxaliplatin causes early hepatocyte proliferation impairment post PH, unaffected by Bevacizumab and unexplained by changes in VEGF-A signalling in a Wistar rat model.
- Affiliations
Citations
Hubert, C., Dahrenmoller, C., Marique, L., Jabbour, N., Gianello, P., & Leclercq, I. (2015). Hepatic regeneration in a rat model is impaired by chemotherapy agents used in metastatic colorectal cancer. European Journal of Surgical Oncology, 41(11), 1471-1478. https://doi.org/10.1016/j.ejso.2015.08.152 (Original work published 2015)